BBNX Stock Beta Bionics (BBNX, $22.18) was a top quarterly gainer, rising +59.8%
at Tickeron.com
Loading...
Beta Bionics (BBNX, $22.18) was one of top quarterly gainers, jumping to $22.18 per share. A.I.dvisor analyzed 144 stocks in the Medical/Nursing Services Industry over the last three months, and discovered that of them (6) charted an Uptrend while of them (3) trended down.
BBNX's Stochastic Oscillator sits in oversold zone for 1 day
Be on the lookout for a price bounce soon.
Technical Analysis (Indicators)
Bullish Trend Analysis
BBNX moved above its 50-day moving average on September 15, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +4.20% 3-day Advance, the price is estimated to grow further. Considering data from situations where BBNX advanced for three days, in 75 of 90 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Aroon Indicator entered an Uptrend today. In 75 of 88 cases where BBNX Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Bearish Trend Analysis
The 10-day RSI Indicator for BBNX moved out of overbought territory on September 23, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 18 similar instances where the indicator moved out of overbought territory. In 14 of the 18 cases, the stock moved lower in the following days. This puts the odds of a move lower at 78%.
The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BBNX as a result. In 15 of 22 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 68%.
The Moving Average Convergence Divergence Histogram (MACD) for BBNX turned negative on September 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 10 similar instances when the indicator turned negative. In 7 of the 10 cases the stock turned lower in the days that followed. This puts the odds of success at 70%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BBNX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.
BBNX broke above its upper Bollinger Band on September 16, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 33 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.318) is normal, around the industry mean (10.853). P/E Ratio (0.000) is within average values for comparable stocks, (98.910). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (8.251) is also within normal values, averaging (39.828).
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. BBNX’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 96 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BBNX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 96, placing this stock worse than average.